Wayne State University
Wayne State University Theses

1-1-2015

Exploring Novel Daptomycin Combinations With
Β-Lactam Against Susceptible & Non-Susceptible
Enterococcus Species
Animesh Raut
Wayne State University,

Follow this and additional works at: https://digitalcommons.wayne.edu/oa_theses
Part of the Medicinal Chemistry and Pharmaceutics Commons
Recommended Citation
Raut, Animesh, "Exploring Novel Daptomycin Combinations With Β-Lactam Against Susceptible & Non-Susceptible Enterococcus
Species" (2015). Wayne State University Theses. 439.
https://digitalcommons.wayne.edu/oa_theses/439

This Open Access Thesis is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne
State University Theses by an authorized administrator of DigitalCommons@WayneState.

EXPLORING NOVEL DAPTOMYCIN COMBINATIONS WITH β-LACTAM
AGAINST SUSCEPTIBLE & NON-SUSCEPTIBLE ENTEROCOCCUS
SPECIES
by
ANIMESH RAUT
THESIS
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
MASTER OF SCIENCE
2015
MAJOR: PHARMACEUTICAL SCIENCES
Approved By: A

-__________________________________
Advisor
Date

DEDICATION

I would like to dedicate my work to my beloved grandparents, Mrs. Indira
Patil and Mr. S.V. Patil for their endless love, support, advises and prayers. I
would also like to thank my parents, Mrs. Chhaya Raut and Mr. Nandakishor
Raut for being strong, believing in me and trusting my instincts. Last but not the
least, a very special thanks to my family, friends and teachers for supporting me
throughout the journey of life.

ii

ACKNOWLEDGMENTS

I would like to take this opportunity to express my gratitude and thank my
mentor, Dr. Michael J. Rybak, Pharm.D., M.P.H. for his constant support and
inputs throughout the course of my M.S. program at Wayne State University. It
was largely due to his help, support, esteemed guidance and encouragement
that this project could take shape and be completed. I thank him for giving
directions to this project and imbibing in an organized approach towards tackling
the relevant problems.
I am deeply indebted to Mr. Jordan Smith, Pharm.D. for his guidance
during the project. His experience and knowledge were crucial in giving a definite
direction to my work. His teaching techniques and inputs during the project were
invaluable and I thank him for sparing his time in guiding me and assisting me in
various aspects of my work.
My special thanks to the ‘Anti-Infective Research Laboratory’ (ARL) team
for their constant support and encouragement. Members at ARL are not just
fellow researchers but are family to me. Their evident dedication to their
respective research provided an atmosphere suitable for accomplishing my goal
and was a constant motivating factor.

iii

I am very thankful to my committee members Dr. Steven Firestine and
Dr. Melody Neely to take out time from their busy schedule and be a part of the
committee. Their crucial contribution and views about my work mean a lot to me.
I sincerely thank Dr. George Sakoulas and his team from University of
California, San Diego for their vital contribution in the fluorescent daptomycin
study part for my project.
I would also like to thank Dr. George Corcoran, our departmental chair
and all other faculty members of the Pharmaceutical Sciences department at
Wayne State University for not only providing students with an research-friendly
atmosphere but also efficiently training us to take on challenging responsibilities
in future.

iv

TABLE OF CONTENTS
DEDICATION……………………………………………………………………………ii
ACKNOWLEDGEMENT………………………………………….....………………...iii
LIST OF TABLES……………………………………………...……………….....…..vii
LIST OF FIGURES……………………………………………………………………viii
CHAPTERS
CHAPTER 1- Introduction……………………………………………………………...1
1.1 Enterococci species……………………………………………………………...…1
1.2 Treatment……………………………………………………………………...…….3
1.2.1

β-lactams………………………….……………………………………..3

1.2.2

Daptomycin……………….……………………………………………...6

1.3 Mechanism of drug resistance in Enterococcus species……………………….8
1.3.1

Resistance to β-lactams………………....……………………..…….10

1.3.2

Resistance to aminoglycosides…………………………………...….11

1.3.3

Resistance to oxazolidinones…….......……………………..……….11

1.3.4

Resistance to glycopeptides..…………………………………….…..11

1.3.5

Resistance to lipopeptides …………………………………………...12

1.4 Proposed mechanism of synergy………………………………………………..15
1.5 Cathelicidin peptide LL-37…………………………………………………..…...18
CHAPTER 2- Hypothesis and specific aims……………………………..…………19

CHAPTER 3- Materials and methods……………………………………………….20

v

3.1 Materials……………………………………………………………………………20
3.1.1 Bacterial strains…….………………………………………………………20
3.1.2 Media………………………………………………………………………..20
3.1.3 Antimicrobials……………………………………………………………....21
3.2 Methods…………………………………………………………………………….21
3.2.1 Susceptibility studies………………………………………………………22
3.2.2 Time-kill experiments…………………………………………………...…23
3.2.3 Binding of fluorescent daptomycin……………………………………….25
3.2.4 LL-37 assay………………………………………...……………………....26
3.2.5 Statistical analysis………………………………………………………....26
CHAPTER 4- Results and discussion……………………………………………….27
4.1 Results…………………………………………………………………….……..…27
4.1.1 Susceptibility studies……………………………….…………….………..27
4.1.2 Time-kill studies………………………………………………….…………31
4.1.3 Fluorescent daptomycin binding studies…………………...……………35
4.1.4 LL-37 assay………..……………………………………………………….37
4.2 Discussion…………………………………………………….……………………39
CHAPTER 5- Conclusion……………………………………………………………..45
REFERENCES…………………………………………………………………………47
ABSTRACT………………………………...…….…………………………………….61
AUTOBIOGRAPHIC STATEMENT…………………………………………….……64

vi

LIST OF TABLES

Table 1. Mechanism of resistance in Enterococcus species…………..…………..9
Table 2. Statistical analysis of reduction in DAP MIC……………………………..28
Table 3. PBP profile for β-lactam antibiotics………………………….…………….42

vii

LIST OF FIGURES

Figure 1. Mechanism of action of β-lactam antibiotics..…………………………….5
Figure 2. Mechanism of action of daptomycin…………………………………….....6
Figure 3. Routes of mechanism of resistance in Enterococcus species……….…8
Figure 4. Proposed mechanism of DAP resistance in Enterococci…………...….14
Figure 5. Proposed mechanism of synergy I.………………………………………16
Figure 6. Proposed mechanism of synergy II………………………………………17
Figure 7. Definition of synergy………………………………………………………..24
Figure 8. Daptomycin MIC values against E. faecium strains 8019 and 5938….29
Figure 9. Daptomycin MIC values against E. faecalis strains 6981 and 7808.....30
Figure 10. Time-kill curves against strain 8019……..……………………………...31
Figure 11. Time-kill curves against strain 5938…………………………………….32
Figure 12. Time-kill curves against strain R6981.………………………………….33
Figure 13. Time-kill curves against strain R7808.………………………………….34
Figure 14. Fluorescent daptomycin binding to E. faecium strain 5928…………..36
Figure 15. Average intensity fluorescently labeled daptomycin against E. faecium
strain 5938…………………………………………………………………37
Figure 16. Percentage survival of Enterococcus species with LL-37……….……38

viii

1

CHAPTER 1
INTRODUCTION

1.1.

Enterococci species
Enterococcus species are Gram-positive bacteria, which have gained

importance as human pathogens for their distinctive property of being resistant to
multiple antimicrobial agents (1). These species have similar physical
characteristics to Streptococci and so are difficult to distinguish (2). Enterococci
are responsible for a variety of infections including infective endocarditis, urinary
tract infections, prostatitis, intra-abdominal infections, wound infections, cellulitis
and concurrent bacteremia (1).
Risk factors for enterococcal infections include prolonged hospitalizations,
patients with compromised immune systems, patients who have undergone
genitourinary surgical procedures or are admitted to the intensive care or the
surgical units, patients who have been fitted with external medical devices like
central intravenous catheter or urinary catheter and patients who have been
administered multiple antibiotics (3). Enterococci are sturdy organisms and can
survive in the hospital environment on various surfaces such as equipment used
for medical procedures, toilets, door handles and beds and can survive heat and
even alcohol preparations.
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Over 17 species of Enterococcus from human origin have been described, out
of which more than 90% are Enterococcus faecium and Enterococcus faecalis
(4). In the last decade, Enterococci have evolved as one of the leading causes of
multiple antibiotic resistant nosocomial infections (5). High level of multi-drug
resistance is one of the defining features of Enterococcus species. They are
known to show characteristic intrinsic and acquired resistance to multiple
antibiotics making them perilous nosocomial pathogens. The majority of the
cases documented demonstrate resistance to β-lactam antibiotics (penicillins,
cephalosporins, carbapenems) as well as aminoglycosides (6). Intrinsic
resistance to several major classes of antibiotics either by acquisition of foreign
genetic material or through mutation, are major contributors to these organisms
being defined as serious nosocomial pathogens (6). Besides being intrinsically
resistant to the β-lactam class of antibiotics, Enterococci have also acquired
resistance to chloramphenicol, tetracyclines, rifampin as well as vancomycin
which has been considered the last line antibiotic defense (7). Enterococcal
resistance to β-lactams is driven by mutations that lead to altered penicillinbinding protein (PBP) profiles which play a key role in the cross-linking of
bacterial cell wall (8). These modified PBPs are able to carry out peptidoglycan
synthesis while bypassing most beta-lactam agents (9). Before we discuss about
resistance and how it works, knowledge about the treatment for such infections is
important.
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1.2.

Treatment
For treating Enterococcus infections, opting for the right drug or

combination of drugs while keeping in mind the toxic side effects is very
important. β-lactams are the most widely used antimicrobial agents to treat
Enterococcal infections (10). They are indicated as the first-line treatment for
such infections. Penicillin, ampicillin to be specific, is usually the drug of choice to
combat Enterococcus infection. If the patient is allergic to penicillin or highresistance is observed then vancomycin is the drug that is preferred.
Unfortunately, virulent strains of Enterococcus that are resistant to vancomycin
have been reported (7). Therefore, therapeutic alternatives to vancomycin are
needed which would combat such infections. One such therapy suggested in the
literature is the therapy using daptomycin. Daptomycin non-susceptible strains
have also been reported and to treat such strains, opting for multi-drug
combination would be optimum (11).

1.2.1. β-lactams and their mechanism of action
β-lactam antibiotics such as penicillins often fail to show bactericidal
activity against vancomycin-resistant enterococci (VRE) species. In some strains,
resistance to penicillins can be developed by intermittent exposure to the
antibiotics (12).
β-lactam antibiotics act by inhibiting the synthesis of peptidoglycan layer,
which is important for cell wall integrity. Peptidoglycan layer is the outermost
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layer of bacterial cell wall. Penicillin-binding proteins (PBP) are responsible for
synthesis of peptidoglycan layer. β-lactam antibiotics inhibit the action of PBPs
and thus peptidoglycan layer is not formed. This leads to prevention of crosslinking of the peptidoglycan layer resulting in a weak cell wall.
As show in figure (1), blue colored band are N-acetylmuramic acid bands
(NAM) and yellow colored bands are N-acetylglucosamine bands (NAG).
Bacterial cell wall is made up of repeating NAM and NAG subunits. Short peptide
chains are connected to the NAM subunits. These short peptide chains are made
up of different compositions but it usually has L-Ala at the proximal end and two
D-Ala on the distal end. Penicillin-binding proteins bind to these peptide chains,
form a cross-link, and expel one molecule of D-Ala as shown in the step (B).
Once the cross-link is formed as shown in step (C), PBPs disengage themselves
from the peptide chains. This results in a healthy cell wall. In step (D) a β-lactam
antibiotic is introduced; it enters the active site of PBP and irreversibly binds to
the PBP making it ineffective as shown in step (E). This process disrupts the
bacterial cell wall synthesis (8).
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Figure (1) Mechanism of action of β-lactam antibiotics, (A.) cell wall before
cross-linking, (B.) expulsion of a D-Ala molecules, (C.) cross-linking of cell wall,
(D.) β-lactam antibiotic attacking the PBP, (E.) irreversible-binding of β-lactam
antibiotic to the PBP
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1.2.2. Daptomycin (DAP) and its mechanism of action
Daptomycin is a lipopeptide drug that shows extensive bactericidal activity
against Gram-positive bacteria (13). The FDA approved dosage for DAP is 46mg/kg, however documented clinical and in vitro results, show better results at
higher

doses

(14-17).

Daptomycin

non-susceptibility

breakpoint

for

Enterococcus species is 4 mg/L according to CLSI (Clinical & Laboratory
Standard Institute) guidelines and any isolate with MIC >4mg/L is termed as
DAP non-susceptible (DNS).
Daptomycin’s mechanism of action is calcium dependent. When DAP
molecules comes in contact with the calcium in the blood they become positively
charged. As shown in figure (2), DAP inserts its lipophilic tail into the bacterial
cell membrane (18). This causes efflux of potassium ions causing the ionconcentration gradient to be destroyed (19). This process leads to rapid
depolarization of the membrane. Rapid depolarization results in failure of biosystems like DNA synthesis, RNA synthesis and protein synthesis, causing cell
death (20).
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Figure (2) Mechanism of action of Daptomycin
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1.3.

Mechanism of drug resistance in Enterococcus species

Figure (3) Routes of mechanism of resistance in Enterococcal species (21)

Figure (3) demonstrates different routes by which Enterococci can develop
resistance towards several antibiotics. We know that Enterococci are intrinsically
resistant to various drugs and can develop resistance to other antibiotics by
genetic mutations and exogenous gene transfer. Table (1) summarizes the
resistance mechanisms for some of major classes of antibiotics.
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Antibiotic

Origin of
Site of
resistance resistance

Intrinsic

Cell wall

Acquired

Cell wall

β-lactams

Notes

Low-affinity PBPs
allow peptidoglycan
synthesis in the
presence of β-lactams
β-Lactamase. Lowlevel constitutive
production may be
missed on routine
laboratory screening
Intrinsic low-level
resistance
in Enterococcus
gallinarium and
Enterococcus
casseliflavus
Mutations in the genes
alter membrane
structure and
composition leading to
either repulsion or
diversion of the
antibiotic from the cell
membrane target

Strategy of
resistance

Decreased
affinity for
PBPs

Drug
inactivation

Acquired
or intrinsic

Cell wall

Daptomycin

Acquired

Cell
membrane

Aminoglycosides

Intrinsic

Ribosome

Polar molecules have
difficulty penetrating to
cytoplasm

Decreased
drug uptake

Ribosome

Mutations in genes
coding for 23S rRNA
and transferable rRNA
methyltransferase (cfr)

Target
modification

Glycopeptides

Linezolid

Intrinsic

Altered target

Altered target

Table (1) Mechanism of resistance in Enterococcus species (22)
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1.3.1. Resistance to β-lactams
Penicillin or ampicillin monotherapy was the treatment of choice taken into
consideration for Enterococcus infections for more than half a century (23).
Resistance against penicillin is developed through production of penicillin-binding
protein (PBP), which plays an important role in cell-wall integrity. Production of
PBP5 is the main cause for ampicillin resistance, due to a low affinity for
penicillins (24). During the 1970s and 1980s, high-resistance to ampicillin was
reported in the United States (25). Another form of ampicillin resistance
documented for E. faecium and E. faecalis is mediated by β-lactamase enzyme
(23). β-lactamase enzyme cleavages through the β-lactam ring of the antibiotic
rendering it inactive (26). Resistance to cephalosporins is associated with
decrease in binding affinity to PBPs present in Enterococcus cells, particularly
PBP5 (27, 28). PBP5 is a class B penicillin-binding protein; it possesses only
transpeptidase enzymatic activity and therefore needs glycosyltransferase to
produce peptidoglycan (22). Studies state that class A PBPs (PBPF, PONA,
PBPZ) are present in E. faecium and E. faecalis. PBPF and PONA penicillinbinding proteins play a role in cephalosporin resistance. PBPZ alone is unable to
synthesize peptidoglycan. It has been documented that deletion of these three
genes resulted in a susceptible mutant. However, this mutant was still active but
shows an altered rate of growth (27, 28). Deletion of class A PBPs showed a
decrease in penicillin and cephalosporin resistance (22).
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1.3.2. Resistance to aminoglycosides
Resistance observed in the case of aminoglycosides is described as lowlevel resistance and high-level resistance. Low resistance causes low uptake of
highly polar drug molecules (29). Such low to moderate level of resistance can
be corrected by combination therapy with active agents like penicillins or
vancomycin (30). However, this combination therapy does not work well with all
the available aminoglycosides due to high-level acquired resistance (31, 32).
High- level resistance is caused by ribosomal mutations that change S12
ribosomal protein leading to altered target binding (33).

1.3.3. Resistance to oxazolidinones
The resistance mechanism against oxazolidinones mainly occurs through
mutations in the genes, which encode 23S ribosomal RNA ribosome-binding site,
thus creating resistance to the drug of this class such as linezolid (34, 35).
Another mechanism of resistance, which is actually more common, is plasmid
mediated, gene cfr that encodes a methlytransferase that modifies position
Å2503 of the 23S rRNA (36).

1.3.4. Resistance to glycopeptides:
Glycopeptides like vancomycin bind to the terminal D-alanine-D-alanine
(D-Ala-D-Ala) of the N-acetylmuramic acid (NAM) and N-acetylglucosamine
(NAG) (37). This prevents cross-linking of the peptidoglycan chains and thus
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inhibits cell wall synthesis (38). Resistance to glycopeptides results from
alterations in peptidoglycan layer synthesis. This alteration results in reduction of
the ability of the drug to bind to cell surface.
Resistance to vancomycin results due to change in the terminal amino acids of
the peptidoglycan precursor from D-alanine-D-alanine to D-alanine-D-lactate (DAla-D-lac) or D-alanine-D-serine (D-Ala-D-Ser) (5). Low-level resistance is
observed with D-Ala-D-Ser-ending precursors, resulting in decreased binding
affinity about seven-fold and high-level resistance is observed with D-Ala-D-Lacending precursors showing about 1000-fold decrease in binding affinity (22).

1.3.5. Resistance to lipopeptides
Daptomycin, which is a potent lipopeptide drug, is used to treat VRE
infections and shows bactericidal activity against Enterococci. Studies carried out
on Daptomycin susceptible (DS) and Daptomycin non- susceptible (DNS) strains
demonstrated that mutation in two genes, one being LiaF involved in cellstressing response to antibiotic (39) and the other being gdpD, which encodes a
glycerol-phosphodiester

phosphodiesterase,

and

cls

encoding

for

cardiolipinsynthase; can cause resistance (40, 41). They play an important role in
metabolism of phospholipids (40). Resistance occurs through altered cell
membrane and cell wall, which then disturbs the interaction of lipopeptides like
daptomycin with the bacteria, causing less depolarization of the cell membrane
(41).
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Over the last two decades, an increasing number of virulent strains resistant
to vancomycin (vancomycin resistant enterococcus, VRE) have been reported,
out of which about 80% are Enterococcus faecium and approximately 9% are
Enterococcus faecalis (42). The presence of multi-drug resistance creates
challenge for the treatment of Enterococcus infections.

•

Proposed mechanism of DAP resistance in enterococci
Recently, Arias et al. proposed two ways in which daptomycin resistance

takes place in Enterococcus (22). The first mechanism is that the drug is diverted
from the division-septum, which is the actual site of action for daptomycin. This
takes place due to the redistribution of cardiolipin micro-domains, which bind to
daptomycin and divert it away from the division-septum. Such mechanism takes
place in Enterococcus faecalis only.
The second mechanism is observed in Enterococcus faecium. In this
mechanism, positively charged daptomycin driven away from the cell membrane
by positive electrostatic repulsion (22). This results mainly from changes in two
genes, YycFG and cls; which cause changes in cell wall stress response (43-45).
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Figure (4) Proposed mechanism of DAP resistance in Enterococcus (22)

Daptomycin non-susceptibility is a major concern. Synergy of daptomycin with βlactams agents has been documented against Staphylococcus species (46-48).
Several documented in vitro studies have been able to demonstrate synergistic
activity against Enterococci with a combination of daptomycin and β-lactams (49,
50). Combinations of daptomycin with β-lactams like ceftaroline (CPT),
ceftriaxone (CRO), and ampicillin (AMP) demonstrated bactericidal results. Infact ceftaroline was observed to restore daptomycin’s susceptibility against DAP-
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NS strain (49). Studies state that lowered cell surface charge and increased
daptomycin binding boost daptomycin’s bactericidal activity (49-51). It has also
been documented that DAP+CPT is effective against E. faecalis; while
DAP+AMP showed enhanced efficacy against E. faecium and E. faecalis (50, 52,
53). Based on these observations, it can be concluded that there is some
mechanism of synergy between daptomycin and β-lactams.

1.4.

Proposed mechanism of synergy
Daptomycin’s bactericidal activity is enhanced in presence of β-lactams.

There have been two proposed mechanisms for this synergy. When a bacterial
cell is exposed to a β-lactam, the negative charge on its surface is increased.
This change increasing the attraction of DAP molecules towards the cell causing
more bactericidal activity (54). The process explained further is self-described but
not yet verified.
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Figure (5) Proposed mechanism of synergy I, (A.) DAP molecules getting
attached to the cell, (B.) DAP molecules attaching to the cell after the cell has
been exposed to β-lactam.
As shown in figure (5A), there is a bacterial cell and there are partial
positive and negative charges. When this cell is exposed to daptomycin, the DAP
molecules attach to the negative molecules on the cell wall. In figure (5B), the
bacterial cell is initially treated with a β-lactam antibiotic and then exposed to
daptomycin. Treating with β-lactam antibiotic increases the number of negative
molecules on the cell wall, which further leads to a higher number of DAP
molecules attaching to the cell surface. This results in more bactericidal activity.
β-lactam antibiotics force bacteria to activate the flipase enzyme. This
enzyme flips the phospholipid bi-layer. This process results due to change of
alanine group to lysine group. The actual mechanism of this process is still
unknown and has not been fully elucidated.
The second and more plausible mechanism is that the action of β-lactam
antibiotic and their target PBP alters the integrity of the cell wall allowing for more
DAP molecules to bind to the cytoplasmic membrane. As shown in figure (6.), a
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perfectly healthy cell wall gets damaged when exposed to β-lactam antibiotics
leading to alteration in the cell wall integrity. When daptomycin is introduced,
more number of DAP molecules penetrate through the loosened and damaged
cell wall easily and get attached to the cell membrane as compared to normal
healthy cell. This causes increase in DAP’s bactericidal activity.

Figure (6) Proposed mechanism of synergy II, (A.) Healthy cell wall and a cell
membrane, (B.) Disruption of cell wall after exposure of β-lactam antibiotics, (C.)
DAP molecules attacking the cell membrane.
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1.5. Cathelicidin peptide LL-37
LL-37 is a cationic peptide, which is a part of the innate human system. It
belongs to the family of polypeptides found in lysosomes of macrophages and
polymorphonuclear leukocytes (PMNs). It is known to show a wide range of
immunomodulatory activates and direct antimicrobial, antifungal and antiviral
properties (55). The mechanism of action of LL-37 is similar to daptomycin (56).
Till date, the actual mechanism behind their activity is not yet determined
conclusively, however the leading hypothesis states that LL37 is membrane
active and it breaks the integrity of the cell membrane of the bacteria (57). As
mentioned earlier, β-lactam antibiotics like CPT, CRO, and AMP enhance
daptomycin’s activity, LL-37 also has some effect on β-lactam activity. LL-37
synergy with β-lactam can also potentially help in avoiding daptomycin
resistance.
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CHAPTER 2
HYPOTHESIS AND SPECIFIC AIMS
Multi-drug resistance is a crucial problem we are facing today. Currently
available therapies are either limited by bacteriostatic activity or the adverse
effects the therapy can cause. New alternate therapies to overcome this
resistance while avoiding such adverse effects are necessary. One such
approach that looks promising is combination therapy. The primary aim of our
study was to test unique combinations of various β-lactam antibiotics with
daptomycin against Enterococcus faecium and Enterococcus faecalis organisms
to assess the potential of this mechanism of synergy and check if some βlactams demonstrate better synergy with daptomycin against Enterococci than
others. Our study also evaluated the ability of β-lactam antibiotics to affect
human cathelicidin peptide LL-37’s antimicrobial activity which could possibly be
vital in indirectly avoiding daptomycin resistance.

20

CHAPTER 3
MATERIALS AND METHODS

3.1.

Materials

3.1.1. Bacterial strains
Fifteen E. faecalis and twenty E. faecium strains were selected for
susceptibility studies. All these strains were ampicillin and vancomycin nonsusceptible. Two clinical strains of E. faecalis and one clinical, isogenic strain
pair of E. faecium were selected for the time-kill studies. E. faecalis strains
R6981 and R7808 were daptomycin-susceptible strains having MIC value of
2mg/L. These clinical strains were chosen due to their resistant nature towards
all the β-lactams tested. An isogenic strain pair of E. faecium was selected out of
which parent strain 8019 was daptomycin-susceptible having a MIC value of
2mg/L and its mutant strain 5938, which is daptomycin non-susceptible having a
MIC value of 32mg/L. As mentioned previously, the susceptibility break-point for
daptomycin is defined as MIC > 4mg/L (58).

3.1.2. Media
Media used to culture Enterococcus species was Brain-heart Infusion agar
(BHI), which is one of the best media for Enterococcal growth (59). Muller-Hilton
broth (MHB). This highly nutritious medium was used for susceptibility studies
and time kill assays. MHB was supplemented with 50mg/L of calcium and
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12.5mg/L of magnesium. As discussed earlier, DAP mechanism of action is
calcium dependent, addition of calcium to the media was important.

3.1.3. Antimicrobials
Daptomycin was the primary drug used for all studies performed.
Daptomycin (Cubicin) was purchased commercially from Cubist Pharmaceutical,
Lexington, MA, USA. A wide-range of β-lactams were selected from broad and
narrow spectrum antibiotics which included 1st, 2nd, 3rd, 4th generation
cephalosporins, carbapenems and penicillins. Cefazolin, cefotaxime, ceftriaxone,
cefepime, ampicillin and ertapenem were purchased commercially from Sigma
Chemical Co., St Louis, MO, USA. Ceftaroline powder was obtained from Actavis
(Formally Forest Laboratories Inc., San Francisco, CA, USA). LL-37, the cationic
cathelicidin antimicrobial peptide was purchased from purchased from AnaSpec,
Fremont, CA, USA.

3.2. Methods
During this study susceptibility studies were carried out with single antibiotic
agents and in combination. Minimum inhibitory concentration values were
determined for all Enterococcus strains. Time kill studies were carried out using
daptomycin alone and in combination with β-lactams. Time kill study results help
to interpret the bactericidal nature of the antibiotics tested and whether or not
synergy by standard definitions was observed. Fluorescent daptomycin binding
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studies were carried out to check if β-lactams had an effect on daptomycin
binding. The LL-37 assay was performed to check if potential synergy, similar to
daptomycin, with β-lactam antibiotics was observed indicating a potential
synergistic action between β-lactams and the innate immune system.

3.2.1. Susceptibility studies
Broth microdilution method was used to determine the minimum inhibition
concentration (MIC) values at ~106 cfu/mL according to CLSI guidelines. All
studies were carried out in duplicates to evaluate reproducibility. The MIC value
of daptomycin was determined with and without presence of β-lactam agents. In
combination therapy, β-lactams were supplemented in the broth at their
respective biological free peaks since Enterococci are intrinsically resistant to βlactams and it is not possible to attain 0.5x MIC in the clinical setting. Evaluation
of all samples was done after an incubation period of 24h at 35oC. Daptomycin
MIC fold reduction from baseline was calculated as the standard broth
microdilution MIC upon daptomycin MIC in presence of respective β-lactams
agents.
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3.2.2. Time-kill experiments
Time kill experiments were performed in MHB supplemented with 50 mg/L
calcium and 12.5 mg/L magnesium as growth media. Each well received an initial
bacterial inoculum of ~106 cfu/mL. Time kill experiments were performed in
duplicate for all antibiotic regimens tested to ensure reproducibility. Daptomycin
and the other antimicrobials were tested at 0.5 x MIC of each respective
organism or biologic concentration, with biologic concentrations being used if 0.5
x MIC was greater than what a standard dose would achieve in serum. We used
0.5x MIC for daptomycin whether the organism was susceptible (breakpoint of
< 4 mg/L) or not. Since all of enterococci tested were resistant to the beta-lactam
we simulated the human pharmacokinetic free Cmax (peak) concentration of the
beta-lactam. All agents were tested alone and in combination with daptomycin
against each strain. All agents were tested alone and in combination with
daptomycin against each strain. 0.1 mL aliquots were obtained from each killing
curve plate well at 0, 4, 8, and 24 hours. These samples were then serially
diluted to the appropriate concentrations and plated using automatic spiral plating
(WASP, DW Scientific, West Yorkshire, England). After 18-24 hours growth on
BHI agar plates, bacterial colonies were counted using a laser colony counter
(ProtoCOL, Synoptics Limited, Frederick, MD). Time kill curves were generated
by plotting mean colony counts (log10 CFU/mL) versus time to compare 24-hour
killing effects of monotherapy and combination antimicrobial exposure. Synergy
was defined according to AAC guidelines 2012 as greater than or equal to 100-
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fold increase in bacterial killing compared to the most active constituent.
Bactericidal activity was defined as greater than or equal to a 3 log10 cfu/mL
reduction from baseline. Figure (6) demonstrates the definition if synergy and
explains how to interpret a time-kill study graph.

Figure (7) Definition of Synergy
Numbers of colonies are represented on the Y-axis and hours of incubation are
on the X-axis. The dotted line represented the growth curve when no drug was
administered. Line below the dotted one represents the growth curve when drug
A was administered. Drug b line indicates a static growth. However, when drug A
and B were administered together the growth cure went down. If the difference
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between the lowest active mono-drug and the combination is greater than 2 log
units, then drug A and drug B are considered synergistic.

3.2.3. Binding of Fluorescent daptomycin (BoDipy)
Fluorescent daptomycin binding studies were carried out on E. faecium
strain 5938, as the strain demonstrated elevated resistance against daptomycin.
Dr. George Sakoulas and his team at University of California, San Diego, carried
out this study for us. Bacteria were grown to an OD600 of 0.6. They were grown
for an additional 1h in the presence of β-lactam agents; 5mg/L of ceftaroline, 20
mg/L of ceftriaxone, 10mg/L of imipenem; and in absence of a β-lactam agent.
They

were

then

incubated

with

8mg/L

of

daptomycin-BoDipy

(boron-

dipyrromethane) for 20min, followed by three times washing with medium to
remove unincorporated label. Samples were then subjected to 1mg/L DAPI stain
and then placed on 1% Agarose pad for imaging in an Applied Precision
deconvolution fluorescence microscope. Images were shot for each sample
using similar camera exposures, for quantification of daptomycin-BoDipy
fluorescence. The average fluorescence intensity of individual pixels for the
background was also measured and then subtracted from the cells to generate
an accurate measurement of daptomycin-BoDipy binding (60).
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3.2.4. LL-37 Assay
All strains were grown to a stationary phase (16 to 20 h) in lysogeny broth
(LB) in either the presence or absence of antimicrobials ampicillin, ertapenem
and ceftaroline; pelleted, washed with PBS, and exposed at an inoculum of 105
CFU/ml to 4-128 µM LL-37 in RPMI-5% LB. The percentage of surviving bacteria
(+/-SD) after 2h of incubation at 35°C was calculated by plating on BHI agar
plates (59).

3.2.5. Statistical analysis
Changes in CFU/mL for the killing curves were compared by one-way
analysis of variance (ANOVA). A p-value of <0.05 was considered significant. All
statistical analyses were performed using SPSS Statistical Software (Release 21,
SPSS, Inc., Chicago, IL).
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CHAPTER 4
RESULTS AND DISCUSSION

4.1. Results
4.1.1. Susceptibility studies
All the Enterococcus strains (15 strains of E. faecalis and 20 strains of E.
faecium) were resistant to vancomycin and ampicillin. MIC values recorded
against β-lactams demonstrated absolute resistance against the agents tested.
The daptomycin MIC values recorded for these strains ranged from 2 to 128
mg/L. However, it was observed that in the presence of β-lactam agents like
ceftaroline, ampicillin, ertapenem, cefotaxime, ceftriaxone, cefepime and
cefazolin; the daptomycin MIC value was reduced. Table (2) describes the
statistical analysis of reduction observed in the daptomycin MIC when given in
combination with various β-lactam agents against the Enterococcus strains.
Ceftaroline combination with daptomycin demonstrated greatest reduction (32fold decrease) in the daptomycin MIC value as compared to other β-lactams in E.
faecium. Statistical analysis in table (2) demonstrates that the average reduction
observed in case of E. faecium was 8.4 ± 8.3-fold. The range of reduction was 4
to 32-fold and median of reduction was 6-fold. In a descending order, ampicillin,
ertapenem, ceftriaxone, cefepime, cefazolin and cefotaxime demonstrated
reduction in daptomycin MIC as well.
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Daptomycin combination MIC reductions against
15 E. faecalis and 20 E. faecium strains
Daptomycin MIC (fold reduction from baseline)
mean

SD

median

range

19.07
12.00
5.00
4.27
7.73
1.80
3.33

17.58
18.98
2.38
3.37
15.76
1.01
0.98

8
2
4
4
4
2
4

2~64
1~64
4~32
2~16
1~64
1~4
2~4

8.40
3.20
6.00
4.00
3.30
2.70
2.80

8.30
2.04
2.31
2.25
2.18
2.45
2.40

6
3
6
4
2
2
2

4~32
1~8
4~8
2~8
2~8
1~8
1~8

E. faecalis
DAP+CPT
DAP+FEP
DAP+AMP
DAP+ERT
DAP+CRO
DAP+CTX
DAP+CFZ
E. faecium
DAP+CPT
DAP+FEP
DAP+AMP
DAP+ERT
DAP+CRO
DAP+CTX
DAP+CFZ

CPT, ceftaroline; FEP, cefepime; AMP, ampicillin; ERT,
ertapenem; CRO, ceftriaxone; CTX, cefotaxime; CFZ, cefazolin.
Table (2) Statistical analysis of reduction in DAP MIC (61)
Ceftaroline demonstrated the greatest DAP MIC reduction for E. faecalis
as well. The greatest DAP reduction in MIC observed was 8-fold, average
reduction recorded was 19.1 ± 17.6-fold with median 8 and range of 2 to 64-fold
reduction as shown in table (2.). In a descending order after ceftaroline, greatest
reduction in DAP MIC was demonstrated by ertapenem, ampicillin, cefepime,
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ceftriaxone, cefazolin and cefotaxime. Figure (7) and figure (8) show graphical
illustration of DAP MIC reduction in E. faecium strains (8019 and 5938), and in E.
faecium strains (R6981 and R7808) respectively that were used for time-kill
studies.

Figure (8) Daptomycin MIC values against E. faecium strains 8019 and 5938, in
the presence of several β-lactam agents. CPT, ceftaroline; ERT, ertapenem;
AMP, ampicillin; FEP, cefepime; CRO, ceftriaxone; FOX, cefoxitin; CFZ,
cefazolin; CTX, ceftriaxone; No Combo, DAP MIC values without the presence of
β-lactam agents(61).
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Figure (9) Daptomycin MIC values against E. faecalis strains R6981 and R7808,
in the presence of several β-lactam agents. CPT, ceftaroline; ERT, ertapenem;
AMP, ampicillin; FEP, cefepime; CRO, ceftriaxone; FOX, cefoxitin; CFZ,
cefazolin; CTX, cefotaxime; No Combo, DAP MIC values without the presence of
β-lactam agents(61).
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4.1.2. Time-kill studies
In figure (9-12), dotted line represents treatment with single drug and solid
lines represent combination drug treatment.

(A.)

(B.)

Figure (10) Twenty-four hour time-kill curves against strain 8019, (A.) Kill curves
with DAP, AMP, CRO, CPT, FEP, ERT alone and in combination with DAP, (B.)
kill curves with CTX, CFZ alone and in combination with DAP.
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(A.)

(B.)

Figure (11) Twenty-four hour time-kill curves against strain 5938, (A.) Kill curves
with DAP, AMP, CRO, CPT, FEP, ERT alone and in combination with DAP, (B.)
kill curves with CTX, CFZ alone and in combination with DAP.
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(A.)

(B.)

Figure (12) Twenty-four hour time-kill curves against strain R6981, (A.) Kill
curves with DAP, AMP, CRO, CPT, FEP, ERT alone and in combination with
DAP, (B.) kill curves with CTX, CFZ alone and in combination with DAP.
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(A.)

(B.)

Figure (13) Twenty-four hour time-kill curves against strain R7808, (A.) Kill
curves with DAP, AMP, CTX, CRO, CPT, FEP, ERT alone and in combination
with DAP, (B.) kill curves with CFZ alone and in combination with DAP.
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In the above figures (9-12); DAP, daptomycin; CPT, ceftaroline; ERT,
ertapenem; AMP, ampicillin; FEP, cefepime; CRO, ceftriaxone; FOX, cefoxitin;
CFZ, cefazolin; CTX, cefotaxime; GC, drug-free growth control.
For strains 8019, 5938 and R6981, ceftaroline, ertapenem, ampicillin,
ceftriaxone and cefepime demonstrated synergy with daptomycin as shown in
figure (9a, 10a and 11a). However, cefazolin and cefotaxime were not synergistic
(Figure 9b, 10b and 11b). Against strain R7808, except cefazolin all other βlactam agents demonstrated synergy with daptomycin (Figure 12a and 12b). The
highest synergistic activity recorded was daptomycin with ertapenem against E.
faecium strain 5938 (P <0.05). Except for this combination all other combinations
demonstrated similar synergistic activity. However, bactericidal activity was not
achieved with the combinations tested against the enterococcal isolates.

4.1.3. Fluorescent daptomycin binding studies
The BoDipy daptomycin binding study was carried out on E. faecium
(5938) strain. Strain samples were pretreated with sub-inhibitory concentrations
of β-lactam agents like ceftaroline, imipenem and ceftriaxone and without any
exposure of β-lactam. Images were captured after treating these samples with
daptomycin. Fluorescent daptomycin was visualized in greenish-yellow color as
shown in figure (13). Quantification results (Figure 14) demonstrated that
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greatest binding of daptomycin was observed in the sample pretreated with
ceftaroline as compared to any other sample (P<0.001). Ceftriaxone and
imipenem show similar daptomycin binding as compared with no pretreatment.

Figure (14) Fluorescent daptomycin (greenish-yellow colored) binding at 8mg/L
to E. faecium strain 5938 cells (blue colored), (a) no pretreatment with β-lactam,
(b) pretreated with 5mg/L of ceftaroline for 20mins, (c) pretreated with 10mg/L of
imipenem for 20mins and (d) pretreated with 20mg/L of ceftriaxone for
20mins(61).
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Figure (15) Average intensity of fluorescently labeled daptomycin (BoDipy)
against E. faecium strain 5938 after pretreatment with several β-lactam agents.
CPT, ceftaroline; CRO, ceftriaxone; IPM, imipenem. Error bars indicate standard
deviation(61).

4.1.4. LL-37 assay
LL-37 demonstrates a bactericidal mechanism of action that is similar to
daptomycin. As per the results of the earlier studies, we demonstrated that βlactam antibiotics show synergy with daptomycin against Enterococcus species.
This study was designed to determine if β-lactam antibiotics also demonstrate
similar synergy with LL-37.
One E. faecalis and two E. faecium strains were chosen for this assay
study. β-lactams chosen for the study were ampicillin, ertapenem and ceftaroline
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and all strains were exposed to subinhibitory concentrations of these β-lactams.
Strains were grown in Lysogeny medium containing LL-37 in the presence and
absence of β-lactam antibiotics.

Figure (16) Percentage survival of Enterococcus species with 128 µM LL-37 in
the presence and absence of free peak concentrations of β-lactam antibiotics
AMP (70mg/L), ERT (15.5mg/L) and CPT (17mg/L). (A.) Strain 6981 (E. faecalis)
(B.) Strain 6370 and (C.) Strain 8019 (E. faecium). Error bars indicate SD(59).
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LL-37 microbicidal assay results are displayed graphically in figure (15).
All the β-lactam antibiotics tested significantly (P <0.001) enhanced killing by LL37. Overall, LL-37 demonstrated maximum microbicidal activity when the strains
were grown in the presence of ceftaroline. Against strain 6981, killing was
significantly (P <0.001) enhanced when strain was exposed to CPT and ERT,
while exposure to AMP yielded similar results as compared to no exposure (P
<0.001) (Figure 15A). Highest killing against E. faecium strains 6370 was
observed when strain was exposed to CPT and ERT as compared to AMP (P
<0.001) (Figure 15B). Against E. faecium strain 8019, all three β-lactam
antibiotics tested showed increased amount of killing by LL-37 as compared to
no exposure (P <0.001) (Figure 15C).

4.2. Discussion
Previous literature has demonstrated that β-lactam antibiotics may act
synergistically with daptomycin. Most of these documented synergy studies were
performed against Staphylococcus species but there is very little information of
such synergistic activity against Enterococcus species. Therefore, the primary
goal of this study was to explore this phenomenon in Enterococci. This study is
one of the largest comparisons of multiple β-lactam antibiotic synergy with
daptomycin against Enterococcus species. Our study demonstrated that β-lactam
antibiotics like ceftaroline, ertapenem, ampicillin, cefepime and ceftriaxone lower
the daptomycin MIC values. These agents also demonstrate synergistic activity
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with daptomycin in time-kill assays against Enterococcus species. However, this
phenomenon does not appear to be true for all β-lactam antibiotics as cefazolin
and cefotaxime demonstrated little to no ability to enhance daptomycin’s
bactericidal activity in time-kill assay. This inability of cefazolin and cefotaxime is
most likely related to differences in the PBP profiles of these agents. Despite the
enterococci being resistant to the beta-lactams, our assumption is that the betalactam even at non-inhibitory or non-lethal concentrations still has some impact
on the cell wall integrity thereby leading to increased daptomycin penetration
through the cell wall and enhanced daptomycin binding at the cytoplasmic
membrane. The difference in the greater synergy activity for ceftaroline,
ampicillin and ertapenem may be related to their unique ability to bind multiple
PBPs.
Every β-lactam antibiotics target specific PBPs to exhibit their respective
inhibitory activity. Resistance to β-lactam antibiotics in enterococci is primarily a
result of mutations leading to altered PBP profiles and hence loss of PBP binding
affinity (62). It has been observed that β-lactam resistant enterococci have
abundant PBP5. PBP5 has low affinity for binding of β-lactam antibiotics and
hence it allows the organism to survive in the presence of a β-lactam agent (63).
However, studies demonstrated that ceftaroline has binding affinity to PBP5 and
therefore demonstrate some activity against resistant Enterococci. One such
study performed by Henry X and group demonstrated the enhanced binding
affinity to PBP5 as compared to other β-lactam agents, which explains why
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ceftaroline demonstrated the greatest synergistic activity with daptomycin against
Enterococci species (62). Some studies have demonstrated that ceftaroline
binding affinity to PBPs 1-4, suggesting that saturations of several PBPs lead to
increase antimicrobial activity. It has been observed in the previous findings that
the saturation of PBPs 1-5 with combination of β-lactam agents increases
antimicrobial activity against E. faecalis (62). Recent clinical data suggest that
combination of ampicillin with ceftriaxone can be effective for enterococcal
infections, which also backs this assumption (64-66). Our study also suggested
that the saturation of PBPs by ceftaroline and to a lesser extent by other β-lactam
agents like ampicillin, ertapenem, ceftriaxone and cefepime, might play an
important role in synergistic activity with daptomycin. Whereas, we presume that
cefotaxime and cefazolin demonstrate more variable binding affinity to PBPs and
no binding to PBP5 and hence fail to demonstrate synergy and enhance
daptomycin’s activity. Similar explanation holds true for enhancement of LL-37’s
activity when the strain is pretreated with β-lactam agents.
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β-lactam
antibiotic
CPT
AMP
CFZ
FEP
CRO
CTX
FOX
ERT

PBP selectivity

PBP1-4 & PBP5
Varies with different
organisms
PBP2
PBP2
PBP4
PBP?

Table (3) PBP profile for β-lactam antibiotic (67).

In addition to the above explanation, there is another possibility by which this
synergistic activity can be explained. Ampicillin restores daptomycin activity in
DAP-NS E. faecium having LiaFSR mutation, a system that is involved in the
regulation of the cell stress response (68). Strain 8019 has been sequenced and
has a known LiaFSR mutation. These mutations are often found in E. faecium
species having MIC values of 2-4mg/L (69). There is a possibility that these
isolates may harbor LiaFSR mutation, and it is possible that several β-lactam
agents may restore daptomycin’s activity against such DAP-NS organisms.
Studies to confer specific mutations that are related with β-lactam synergy need
more investigation into LiaFSR mutations; mutations present in cardiolipin
synthase (cls) gene, which confers changes in membrane orientation of
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cardiolipins in the E. faecalis cell membrane, and yyCFGHIJ, a regulator of cell
wall homeostasis (68, 70). A study carried out by Cesar Arias and his group at
Houston demonstrated synergy between ampicillin and daptomycin on strains of
E. faecium with LiaFSR mutations (69).
Resistance to daptomycin therapy among E. faecalis has been
demonstrated by diverting the daptomycin molecules away from the division
septum, which is the primary site of action (70). In addition, resistance in E.
faecium is demonstrated by lack of daptomycin binding (49, 50). Our study
demonstrated that presence of subinhibitory concentration ceftaroline increased
daptomycin activity against a DAP-NS strain 5938. Among all the β-lactam
antibiotics tested, ceftaroline was superior to all others against this strain, which
may be explained by the enhanced PBP binding profile of ceftaroline.
Daptomycin in combination with β-lactam antibiotics demonstrated
impressive results in broth microdilution MIC testing. There is clinical evidence of
ceftaroline

demonstrating

synergistic

activity

with

daptomycin

against

enterococcal infections; ampicillin is also frequently administered in combination
therapy to treat such infections (52). Ertapenem is a broad spectrum Gramnegative β-lactam antibiotic that shows potential in a setting of a prolonged
antibiotic course to treat acute infections, as its simple one daily dosing regimen
allows for uncomplicated outpatient therapy as compared to other more
frequently administered parenteral β-lactam antibiotics (71).
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β-lactam antibiotics have also demonstrated enhancement of LL-37’s
antimicrobial activity. The highest LL-37’s activity was achieved when strain was
pretreated with ceftaroline as compared to other β-lactam agents. This further
substantiates the ability of β-lactam antibiotics to improve antimicrobial activity
including enhancing components of the innate immune system.
Further studies are warranted on a variety of different enterococcal
strains to confirm the reproducibility of these results and the conclusion that our
study suggests.
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CHAPTER 5

CONCLUSION
With the increasing number of vancomycin-resistant and ampicillinresistant Enterococci species, therapeutic alternative therapies to combat such
infections are essential. Daptomycin is a bactericidal antibiotic and is used to
treat VRE infections. However, daptomycin non-susceptibility is also a concern.
Our study demonstrated the ability of β-lactam antibiotics to provide synergistic
activity with daptomycin against such infections. In addition, this study also
validates the ability of β-lactams to restore daptomycin’s activity in some
enterococcal strains demonstrating non-susceptibility. Also, our study suggests
that if high-dose daptomycin were administered in combination with β-lactam
antibiotics at an early stage, the therapy would demonstrate effective enhanced
bactericidal activity and potentially avoid the development of daptomycin
resistance. Our results suggest that use of β-lactam antibiotics with LL-37
increases antibacterial activity of the cationic peptide LL-37 thus modulating the
immune system. The finding suggests that the use of early β-lactam therapy may
reduce the likelihood that DAP resistance may develop. Future studies should
explore whether the use of DAP in combination with β-lactams could also be
DAP dosage sparing reducing the need for high-dose DAP regimens for the
treatment of enterococcal infections. Our data would also suggest that not all
enterococci may be susceptible to daptomycin plus a beta-lactam. Based on
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enterococcal PBP profiling or detection of specific mutations such as the
presence of liaSFR mutations, it may be possible in the future to individualize
patient therapy with technology.
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Objective: Enterococcus faecalis and Enterococcus faecium are generally
resistant to daptomycin and β-lactam antibiotics. However, documented in vitro
data suggests synergy between several β-lactam antibiotics and daptomycin
against resistant organisms. Primary goal of the study was to check various
combinations of β-lactam antibiotics with daptomycin (DAP) and assess the
potential of synergy and conclude which could be the superior combination.
Study also evaluated potential of β-lactam antibiotics to enhance activity of LL37, which is a cationic peptide demonstrating bacteriostatic activity similar to
DAP.
Methods: Fifteen E. faecalis and twenty E. faecium strains were evaluated DAP
enhancement via combination MICs. DAP MICs were obtained by broth
microdilution in the absence and presence of various β-lactam antibiotics. Time-
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kill studies were carried out on two E. faecalis (R6981 and R7808) and one
isogenic DAP-susceptible/ DAP-non-susceptible E. faecium strain (8019/5938).
DAP was tested at 0.5x MIC with β-lactam antibiotics at free peak
concentrations. Fluorescent DAP (BoDipy) was used to evaluate DAP binding
studies on an E. faecium strain (5938). Two E. faecium (R6370 and 8019) and
one E. faecalis (R6981) strains were chosen for evaluating enhancement of
killing by LL-37 in the presence and absence of β-lactam antibiotics.
Results: Highest reduction in DAP MIC value was observed when given in
combination with ceftaroline. Ceftaroline (CPT), ertapenem (ERT), ampicillin
(AMP), cefepime (FEP) and ceftriaxone (CRO) demonstrated synergy with DAP
in time-kill studies. However, DAP synergy was observed with cefazolin (CFZ)
and cefotaxime (CTX) only in one strain (R7808). In DAP binding studies,
ceftaroline enhanced the DAP binding most as compared to other β-lactam
antibiotics tested (P <0.001). In LL-37 assay study, CPT, AMP and ERT
enhanced LL-37’s killing against strain 8019. For strain R6981 and R6370, LL-37
demonstrated better killing with CPT and ERT as compared to AMP (P <0.001).
Conclusion: Results of out study conclude that the use of DAP in combination
with β-lactam antibiotics to treat resistant Enterococcus infections is lucrative.
Combination regimens as compared to DAP alone demonstrate better killing.
Combination also enhanced LL-37’s activity, which could possibly be a way to
avoid DAP resistance. Overall, our data supports the evidence that combination
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therapy of daptomycin with β-lactams maybe be helpful in combating nonsusceptible Enterococcus strains.
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